Tianjin Chase Sun Pharmaceutical (SHE:300026) received approval from China's National Medical Products Administration for the clinical trials of nafamostat mesylate for injection, according to a Friday disclosure on the Shenzhen bourse.
The drug is used to prevent coagulation of perfused blood during extracorporeal circulation, such as hemodialysis and plasma exchange.
The pharmaceutical company's shares rose less than 3% at the close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.